Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04576286
Other study ID # FMASU R32/2020
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 24, 2020
Est. completion date August 1, 2021

Study information

Verified date October 2020
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

En bloc resection of bladder tumors (ERBT) may improve staging quality and perioperative morbidity and influence tumour recurrence


Description:

Modern laser technology has led to new alternatives to conventional TURBT (cTURBT). The advocates of ERBT have three goals: to improve resection quality, lower perioperative complication rates, and decrease recurrence rates at resection sites. The present study is the first to compare the results of laser and electric en bloc resection of bladder cancer with respect to the aforementioned goals.

we aimTo compare the clinical outcome in the form of safety and efficacy between Holmium and bipolar transurethral en bloc resection of urinary bladder tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date August 1, 2021
Est. primary completion date August 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients of both sexes presented with urinary bladder tumor aiming for complete resection as diagnosed by Ultrasound with or without CT prior histopathological assessment.

Exclusion Criteria:

- Patients with signs of extravesical tumor extension where complete resection will not beneficial or unable to proceed to complete resection due to huge tumor burden either huge single tumor more than 5 cm or multiple tumors that are not candidate for complete resection.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Holmium versus Bipolar en bloc transurethral resection
After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician. Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B.

Locations

Country Name City State
Egypt Ain Shams University Hospitals Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary number of participant with Conversion to the TURBT conversion from the enbloc way of resection to the standard trans-urethral resection of bladder tumors intraoperative finding
Secondary Operative time calculation of operative time in minutes intraoperative finding
Secondary Presence of detrusor muscle in resected sample presence of muscle layer in the pathological specimen (Yes/No) one day after surgery during pathological evaluation
Secondary Resected specimen's edge tumor free margin (Yes/No) one day after surgery during pathological evaluation
Secondary intraoperative complication: bladder perforation (Yes/No) bladder perforation intraoperative
Secondary Incidence of obturator reflex (Yes/No) energy induced obturator reflex intraoperative
Secondary hematuria (Yes/No) postoperative complication up to 2 weeks
Secondary Post-operative catheterization time in hours time till catheter removal in days postoperative complication up to 2 weeks
Secondary Postoperative irrigation time in hours hours for the need of postoperative irrigation postoperative in hours maximum 1 day
Secondary Recurrence rate of tumors according to time interval recurrence of tumor in the follow up cystoscopy 1 year
Secondary Recurrence rate of tumors according to tumor location recurrence of tumor in the follow up cystoscopy in the same site or in different site 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05429710 - SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Not yet recruiting NCT05097105 - Role of Diffusion -Weighted MRI in Evaluation of Urinary Bladder Masses
Completed NCT02966535 - The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial N/A
Completed NCT02977143 - Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery N/A
Recruiting NCT04144270 - The Importance of Muscle Function in Patients With Disseminated Bladder Cancer
Completed NCT05946369 - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Recruiting NCT05786716 - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations Phase 2/Phase 3
Recruiting NCT06238479 - A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Phase 1
Completed NCT02311101 - Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer Phase 1
Recruiting NCT04811846 - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood N/A
Not yet recruiting NCT06465069 - A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors Phase 1
Completed NCT02857634 - Confocal Microscopy Dual Band in the Management of Bladder Cancer
Recruiting NCT04561362 - Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Phase 1/Phase 2
Recruiting NCT04442724 - Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy N/A
Recruiting NCT04029948 - Laser vs. Electorsurgical Enbloc Resection of Bladder Tumours N/A
Terminated NCT03389438 - Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Phase 2
Terminated NCT02952989 - A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06237920 - Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab Phase 2
Completed NCT03785925 - A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Phase 2
Completed NCT03636256 - Evaluation of NanoDoce® in Participants With Urothelial Carcinoma Phase 1/Phase 2